Hamps Bio Limited
₹
None%
- close price
About
Incorporated in 2007, Hamps Bio Ltd is in the business of Pharmaceutical Formulation and Freeze-Drying Ingredient Manufacturing and Distribution[1]
Key Points
- Market Cap ₹ 22.2 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 44.4
- Book Value ₹
- Dividend Yield %
- ROCE 21.3 %
- ROE 21.1 %
- Face Value ₹
Pros
- Company has reduced debt.
Cons
- Working capital days have increased from 57.6 days to 97.4 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 5.34 | 5.58 | 6.48 | |
| 4.72 | 4.71 | 5.31 | |
| Operating Profit | 0.62 | 0.87 | 1.17 |
| OPM % | 11.61% | 15.59% | 18.06% |
| 0.00 | 0.01 | 0.03 | |
| Interest | 0.19 | 0.18 | 0.15 |
| Depreciation | 0.33 | 0.34 | 0.40 |
| Profit before tax | 0.10 | 0.36 | 0.65 |
| Tax % | -20.00% | 0.00% | 23.08% |
| 0.12 | 0.36 | 0.50 | |
| EPS in Rs | |||
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 21% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 1.50 | 1.50 | 1.96 |
| Reserves | -0.49 | -0.14 | 1.41 |
| 2.04 | 1.74 | 1.05 | |
| 0.60 | 0.86 | 0.73 | |
| Total Liabilities | 3.65 | 3.96 | 5.15 |
| 2.15 | 2.61 | 2.56 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.04 | 0.00 | 0.00 |
| 1.46 | 1.35 | 2.59 | |
| Total Assets | 3.65 | 3.96 | 5.15 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 0.33 | 1.23 | -0.29 | |
| 0.51 | -0.75 | -0.37 | |
| -0.94 | -0.48 | 0.67 | |
| Net Cash Flow | -0.10 | 0.00 | 0.01 |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 47.16 | 49.71 | 55.76 |
| Inventory Days | 94.57 | 75.03 | 264.09 |
| Days Payable | 63.05 | 103.42 | 60.12 |
| Cash Conversion Cycle | 78.69 | 21.32 | 259.73 |
| Working Capital Days | 51.26 | 24.20 | 97.45 |
| ROCE % | 17.56% | 21.28% |
Documents
Annual reports
No data available.
Business Overview:[1]
HBL is in the business of ethical marketing and distribution of pharmaceutical formulations across wide range of dosage including tablets, syrups, capsules, injectables, oil, gel and powder used as medicine & nutrition supplements as well as the manufacturing of freeze dried and frozen products such as fruits, vegetables, herbs and flowers.